Why is "AQW051" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-04-07 23:32:28
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
This topic is not currently in the ranking.
Wikipedia Overview
AQW-051 also known as VQW-765 is an orally available, highly selective partial agonist of the alpha-7 nicotinic receptor (nAChR) developed by Novartis as a central nervous system agent aimed at improving cognitive function in disorders such as schizophrenia and Alzheimer's disease, and for reducing L-Dopa–induced dyskinesias in Parkinson's disease. AQW-051 had reached Phase 2 clinical trials for conditions like schizophrenia and Parkinson’s disease, but development for Alzheimer’s disease has been discontinued.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
No recent news articles found.
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.